Patents Issued in March 7, 2019
  • Publication number: 20190070117
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to methods for vitrifying biological preparations, including peptides, antigens, antibodies, cells, and the like.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Applicant: Merial, Inc.
    Inventor: Noel Yves Henri Jean Genin
  • Publication number: 20190070118
    Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 4, 2018
    Publication date: March 7, 2019
    Inventor: John R. PLACHETKA
  • Publication number: 20190070119
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: September 4, 2018
    Publication date: March 7, 2019
    Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20190070120
    Abstract: The present invention relates to a binder tree pharmaceutical composition comprising canagliflozin or a prodrug or a pharmaceutically acceptable salt thereof, and one or more 5 pharmaceutically acceptable excipients, wherein the said composition is devoid of canagliflozin hemihydrate, and having acceptable chemical stability, polymorphic stability & comparative dissolution and bioequivalence profile to that of INVOKANA® tablets.
    Type: Application
    Filed: March 9, 2017
    Publication date: March 7, 2019
    Applicant: Aurobindo Pharma Ltd.
    Inventors: Satyabrata Barik, Venugopala Chokkasandra Jayarama Reddy, Sivakumaran Meenakshisundaram
  • Publication number: 20190070121
    Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Applicant: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
    Inventors: Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
  • Publication number: 20190070122
    Abstract: To provide to a transdermal absorption-type patch preparation containing zonisamide, that is a transdermal absorption-type patch preparation containing zonisamide or an alkali metal salt thereof, being capable of maintaining a high concentration of a drug in a dissolved state in the preparation and exhibiting sufficient and sustained drug efficacy. A transdermal absorption-type patch preparation containing an adhesive layer, the adhesive layer containing zonisamide or an alkali metal salt thereof, an adhesive agent containing a (meth)acrylic copolymer having a pyrrolidone group, and a transdermal absorption promoter containing N-alkylpyrrolidone.
    Type: Application
    Filed: March 24, 2017
    Publication date: March 7, 2019
    Applicants: TEIKOKU SEIYAKU CO., LTD., Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Katsuyuki INOO, Daiki TAKANO
  • Publication number: 20190070123
    Abstract: Provided is a transdermal preparation including: a phenylpiperazine derivative; an organic acid; an ester-based solvent; and an organic sulfoxide.
    Type: Application
    Filed: November 8, 2018
    Publication date: March 7, 2019
    Inventors: Satoshi YONEYAMA, Taisuke ENDO
  • Publication number: 20190070124
    Abstract: Disclosed are stable compositions comprising at least one CB2 receptor selective or highly selective agonist and optionally at least one antipsychotic for use in the treatment of mental disorders, methods of preparing such compositions and methods of treating mental disorders using same. Disclosed are also compositions comprising beta caryophyllene (BCP) or HU-308 for use in the treatment of mental disorders one of which is schizophrenia, methods of making such compositions and methods of treating mental disorders one of which is schizophrenia.
    Type: Application
    Filed: March 3, 2017
    Publication date: March 7, 2019
    Inventor: Sharon Anavi-Goffer
  • Publication number: 20190070125
    Abstract: The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 7, 2019
    Applicant: NOVALIQ GMBH
    Inventors: Dieter SCHERER, Ralf GRILLENBERGER, Frank LÖSCHER, Hartmut VOSS
  • Publication number: 20190070126
    Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.
    Type: Application
    Filed: March 8, 2017
    Publication date: March 7, 2019
    Applicant: N.V. NUTRICIA
    Inventor: Mattheus Cornelis DE WILDE
  • Publication number: 20190070127
    Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.
    Type: Application
    Filed: October 3, 2018
    Publication date: March 7, 2019
    Inventor: Qi Long Lu
  • Publication number: 20190070128
    Abstract: The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 7, 2019
    Inventors: Geoffrey GUY, Stephen WRIGHT, James BRODIE, Marie WOOLLEY-ROBERTS, Rafael MALDONADO, Daniela PAROLARO, Livio LUONGO, Joanna NEILL
  • Publication number: 20190070129
    Abstract: The present invention relates to use of a composition comprising a panduratin derivative or a boesenbergia pandurata extract as an effective ingredient, which suppresses the differentiation of osteoclasts to exhibit the effect of treating, preventing or ameliorating bone loss diseases and which can be used safely as a natural material without side effects, thus finding effective applications in drugs, quasi-drugs, or foods.
    Type: Application
    Filed: August 28, 2018
    Publication date: March 7, 2019
    Inventors: Jae Kwan Hwang, Si Yeon Kim, Mi Bo Kim
  • Publication number: 20190070130
    Abstract: A composition contains curcumin and can treat or prevent sarcopenia, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.), increase muscle functionality, and/or improve recovery of muscle functionality after muscle atrophy. The composition can be administered to an individual who is elderly and/or frail, optionally in a composition that further includes an omega-3 fatty acid and/or a protein source.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 7, 2019
    Inventors: Marie Noelle Horcajada, Fanny Membrez, Denis Breuille, Claire Boutry
  • Publication number: 20190070131
    Abstract: The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets.
    Type: Application
    Filed: August 28, 2018
    Publication date: March 7, 2019
    Inventors: G. Lynn Howard, Nicholas J. Farina, Edward J. Walters, Christopher Howard
  • Publication number: 20190070132
    Abstract: The invention features compositions, methods, and kits containing (i) one or more cysteamine precursor compounds convertible to cysteamine in vivo, and (ii) optionally agents to enhance that conversion, formulated to produce a spectrum of pharmacokinetic profiles of cysteamine that can be tailored to individual patients and diseases. The invention also features varying modes of administration of the therapeutic substances in the treatment of cystinosis and other cysteamine sensitive disorders. In particular, formulations combining active ingredient(s) with pharmaceutical excipients that permit sustained cysteamine plasma concentrations are featured.
    Type: Application
    Filed: March 17, 2017
    Publication date: March 7, 2019
    Inventors: Vincent P. STANTON, Jr., Patrice P. RIOUX
  • Publication number: 20190070133
    Abstract: The present application relates to a pharmaceutical composition/formulation for improving or preventing progression of chronic kidney disease (CKD) caused due to inflammation and/or Klotho under expression. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Palmitoylethanolamide (PEA), Cholecalciferol and one or more natural ingredients. The invention also provides various formulations and methods of preparing the same.
    Type: Application
    Filed: August 22, 2018
    Publication date: March 7, 2019
    Inventors: Ankit Shyam Singh, Vedprakash Mishra, Neelima Tongra
  • Publication number: 20190070134
    Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
    Type: Application
    Filed: November 6, 2018
    Publication date: March 7, 2019
    Inventors: Matthew J. D'ONOFRIO, David A. GONYER, Shirish A. SHAH, Stuart J. MADDEN
  • Publication number: 20190070135
    Abstract: A composition for mixing with water for use as an oral rinse, comprising monobasic sodium phosphate, dibasic sodium phosphate, sodium chloride, calcium chloride, and an analgesic/anaesthetic such as benzocaine/lidocaine.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Applicant: Forward Science Technologies, LLC
    Inventors: Brian Pikkula, Robert J. Whitman
  • Publication number: 20190070136
    Abstract: Described herein are parenteral compositions of carmustine. More particularly, described herein are ready to use parenteral compositions of carmustine in the form of solutions.
    Type: Application
    Filed: September 4, 2018
    Publication date: March 7, 2019
    Inventors: BANDI PARTHASARADHI REDDY, PODILE KHADGAPATHI, BANDARI SREEDHAR
  • Publication number: 20190070137
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: October 22, 2018
    Publication date: March 7, 2019
    Applicant: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Publication number: 20190070138
    Abstract: The invention pertains to a solid dosage form comprising vigabatrin; a superdisintegrant, advantageously chosen from the list consisting of crospovidone, a cellulose derivative and a starch derivative; a non-reducing sugar, advantageously chosen from the list consisting of mannitol, xylitol, and sorbitol; and a stearate derivative, advantageously a stearate or stearyl fumarate salt, more advantageously sodium stearyl fumarate or magnesium stearate.
    Type: Application
    Filed: March 10, 2016
    Publication date: March 7, 2019
    Inventors: Charles UZARAMA, Patrick GOSSELIN, Marie-Pierre FLAMENT
  • Publication number: 20190070139
    Abstract: Ingestion or administration of cysteine is effective for improving physical capacity for activity and provides a superior improving effect as compared to conventional compositions for the enhancement of improvement of physical capacity for activity relating to physical functions.
    Type: Application
    Filed: September 13, 2018
    Publication date: March 7, 2019
    Applicant: AJINOMOTO CO., INC.
    Inventors: Yoshihito NOGUSA, Ami MIZUGAKI
  • Publication number: 20190070140
    Abstract: The present invention relates to use of a composition comprising protectin DX of Formula 1 as an effective ingredient for treating, preventing or ameliorating hyperlipidemia or fatty liver disease and/or protecting the liver.
    Type: Application
    Filed: August 29, 2018
    Publication date: March 7, 2019
    Inventors: Yuan Lu Sun, Ji Hoon Jeong, Tae Woo Jung
  • Publication number: 20190070141
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Publication number: 20190070142
    Abstract: Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (HSCs), such as non-alcoholic fatty liver disease (NAFLD), fibrosis, and liver cancer, using ammonia-lowering therapies.
    Type: Application
    Filed: July 3, 2018
    Publication date: March 7, 2019
    Inventors: Rajiv Jalan, Rajeshwar Prosad Mookerjee, Krista Rombouts, Fausto Andreola, Francesco De Chiara, Karen Louise Thomsen
  • Publication number: 20190070143
    Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).
    Type: Application
    Filed: June 15, 2016
    Publication date: March 7, 2019
    Inventors: Pierre Boulas, Erwin Irdam, Shyam B. Karki, William F. Kiesman, Cheuk-Yui Leung, Yiqing Lin, Andrea Trementozzi, Peter Zawaneh
  • Publication number: 20190070144
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 7, 2019
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Publication number: 20190070145
    Abstract: This document relates to materials and methods for treating fibrosis (e.g., pulmonary fibrosis). For example, this document provides methods for using one or more fatty acid synthase (FASN) inhibitors to treat a mammal having fibrosis (e.g., pulmonary fibrosis), and/or a complication associated with fibrosis (e.g., hypoxia caused by pulmonary fibrosis).
    Type: Application
    Filed: March 22, 2017
    Publication date: March 7, 2019
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Edward B. Leof, Ruth Lupu, Jeong-Han Kang, Mi-Yeon Jung
  • Publication number: 20190070146
    Abstract: Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions.
    Type: Application
    Filed: November 1, 2018
    Publication date: March 7, 2019
    Inventors: Asim Kumar Debnath, Francesca Curreli, Peter D. Kwong, Young Do Kwon
  • Publication number: 20190070147
    Abstract: Provided herein are stable enalapril oral liquid formulations. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: October 31, 2018
    Publication date: March 7, 2019
    Inventors: Gerold L. Mosher, David W. Miles
  • Publication number: 20190070148
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Application
    Filed: July 5, 2018
    Publication date: March 7, 2019
    Inventors: Phil SKOLNICK, Anthony BASILE, Zhengming CHEN, Joseph W. EPSTEIN
  • Publication number: 20190070149
    Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.
    Type: Application
    Filed: April 26, 2018
    Publication date: March 7, 2019
    Inventors: Bradley Teegarden, Dennis Chapman, Juyi Choi, Konrad Feichtinger, Sangdon Han, Honnappa Jayakumar, Thuy-Anh Tran, Jay Xu, Ning Zou
  • Publication number: 20190070150
    Abstract: A method of treating or preventing type C Hepatic Encephalopathy in a human patient diagnosed with cirrhosis by administering a composition containing at least 200 mg biotin to the human patient daily.
    Type: Application
    Filed: September 18, 2018
    Publication date: March 7, 2019
    Applicant: MEDDAY PHARMACEUTICALS
    Inventor: Frédéric SEDEL
  • Publication number: 20190070151
    Abstract: The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(?O)— wherein Y1 is a group such as —C(?O)—, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
    Type: Application
    Filed: November 1, 2018
    Publication date: March 7, 2019
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Minoru OKADA, Masaya KATO, Norifumi SATO, Tetsuyuki UNO, Hideki KITAGAKI, Junpei HARUTA, Hidetaka HIYAMA, Tomonori SHIBATA
  • Publication number: 20190070152
    Abstract: The present application discloses a pharmaceutical preparation comprising a de-epoxidized epothilone derivative, and especially relates to a preparation formulation of a compound with reduced allergens and toxicity; and also relates to the use thereof in the treatment of tumours, especially the use thereof in the treatment of solid tumours that are resistant to and fail to respond to other conventional chemotherapeutic agents, as well as the use thereof in the treatment of cancers alone or in combination with other tumour drugs or auxiliary drugs.
    Type: Application
    Filed: February 6, 2017
    Publication date: March 7, 2019
    Applicants: Beijing Biostar Technologies Ltd., Chengdu Biostar Pharmaceuticals, Ltd.
    Inventors: Li Tang, Rongguo Qiu
  • Publication number: 20190070153
    Abstract: A method of treating a pulmonary disease in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that inhibits the renin-angiotensin signaling pathway.
    Type: Application
    Filed: October 11, 2016
    Publication date: March 7, 2019
    Inventors: Mitchell L. Drumm, Rebecca J. Darrah, Frank J. Jacono, Anna L. Mitchell
  • Publication number: 20190070154
    Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial Sand viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
    Type: Application
    Filed: June 24, 2016
    Publication date: March 7, 2019
    Inventors: Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly
  • Publication number: 20190070155
    Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
    Type: Application
    Filed: July 31, 2018
    Publication date: March 7, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Marinus Jacobus VERWIJS, Rossitza Gueorguieva ALARGOVA, Ritu Rohit KAUSHIK, Irina Nikolaevna KADIYALA, Christopher YOUNG
  • Publication number: 20190070156
    Abstract: The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS), fibromyalgia (FM) and depression, as well as of combinations thereof. Related treatment methods, pharmaceutical compositions and combination kits are also disclosed.
    Type: Application
    Filed: May 11, 2016
    Publication date: March 7, 2019
    Inventors: Arvid Carlsson, Carl-Gerhard Gottfries
  • Publication number: 20190070157
    Abstract: Disclosed herein is Hyperbaric solution for injection of Levobupivacaine Hydrochloride which comprises Levobupivacaine Hydrochloride; base/acid to adjust the pH and baricity adjuster to modify Baricity of the solution injection.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 7, 2019
    Inventors: Neeta JOSHI, Rahul NARKHEDE
  • Publication number: 20190070158
    Abstract: A monodose veterinary composition for topical application (spot on) for canines, the said composition comprising: (a) Imidacloprid, between 8.18 and 10.00%, (b) Moxidectin, between 2.86 and 3.50%, (c) Praziquantel, between 8.18 and 10.00%, and (d) an aprotic solvent selected from Dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF) and their mixtures, between 65.45 and 80.00%; together with excipients acceptable from the veterinary viewpoint, where the percentages are related to the composition's total weight.
    Type: Application
    Filed: May 16, 2017
    Publication date: March 7, 2019
    Applicant: LABYES USA, LLC
    Inventors: Carlos D. CORRALES, Jorge A. DALE
  • Publication number: 20190070159
    Abstract: The invention provides a potassium-competitive acid blocker (P-CAB) for use in the treatment, prevention and/or reduction of gastro-esophageal reflux disease (GERD) symptoms in patients who are partial responders to a proton pump inhibitor (PPI). The P-CAB may, for example, be selected from 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine (vonoprazan), revaprazan (YH1855), YH4808, RQ-4 and CS-526, or a salt thereof.
    Type: Application
    Filed: November 1, 2018
    Publication date: March 7, 2019
    Inventors: Richard JENKINS, Mark HIBBERD
  • Publication number: 20190070160
    Abstract: A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 7, 2019
    Applicant: AiViva Holding Limited
    Inventors: Diane Tang-Liu, Tiffany Liu
  • Publication number: 20190070161
    Abstract: The instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists. The CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache.
    Type: Application
    Filed: September 10, 2018
    Publication date: March 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Majid Mahjour, Leonardo R. Allain, Sutthilug Sotthivirat, Russell G. Maus, Rebecca Nofsinger, Lisa Lupton, Wei Xu, Francis Flanagan
  • Publication number: 20190070162
    Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
    Type: Application
    Filed: February 20, 2018
    Publication date: March 7, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Patricia Hurter, William Rowe, Christopher R. Young, Adriana Costache, Patrick R. Connelly, Mariusz Krawiec, Yuchuan Gong, Yushi Feng, Martin Trudeau
  • Publication number: 20190070163
    Abstract: Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Applicant: TOCHIGI INSTITUTE OF CLINICAL PATHOLOGY
    Inventor: Masao SUGAMATA
  • Publication number: 20190070164
    Abstract: A montelukast composition having a therapeutically effective amount of montelukast in a sustained release is disclosed. A montelukast composition having a therapeutically effective amount of montelukast in an immediate release and sustained release is also disclosed. A method for treating a patient with chemo brain by the administration of a composition comprising two portions, where the first portion comprises a first quantity of therapeutically effective amount montelukast in an immediate release formulation, and a second portion contains a second quantity of therapeutically effective montelukast in a release-rate modifier, and where the total quantity of montelukast is from 20 mg to 200 mg.
    Type: Application
    Filed: November 7, 2018
    Publication date: March 7, 2019
    Inventor: Jack William Schultze
  • Publication number: 20190070165
    Abstract: In some aspects, the present disclosure provides compounds of the formula: Formula (I) wherein the variables are defined herein are provided, which may be used to inhibit viral replication. In some embodiments, these compounds may be used to treat an infection of hepatitis B virus.
    Type: Application
    Filed: March 16, 2017
    Publication date: March 7, 2019
    Applicants: Saint Louis University, Ecole Nationale Supérieure de Chimie de Lille
    Inventors: John Edwin TAVIS, Philippe COTELLE, Fabrice BAILLY
  • Publication number: 20190070166
    Abstract: The present invention teaches a method, system and process for curing, treating and diagnosing arthritis, diabetes and other related autoimmune diseases. By intercepting and mitigating the disease process at the point of origination prevents the disease from developing and stops the lineage of cells causing disease symptoms. This fundamental system addresses cellular events where the immune reaction is emerging thereby preventing advance of the cascade that feeds the disease. Modulating activity of the errant protein at this initiating point in the immune response blocks the autoimmune cascade and prevents formation of secondary and tertiary effects that will characterize the disease. As the cascade progresses, the number of participating enzymes and pathways compounds so that each progression step further from the initiation point requires increasingly complex therapies. Thus, by treating the primary cause, secondary and tertiary symptoms do not appear.
    Type: Application
    Filed: October 5, 2017
    Publication date: March 7, 2019
    Inventor: Richard Postrel